How much is the mortality rate after rectum cancer operation

summary

My grandfather lost his appetite these days, lost his temper, got upset, had difficulty breathing, couldn't wake up, and didn't sleep well. His family took him to the hospital for physical examination. The doctor said that he had rectal cancer. After treatment, the situation is much better now. Now let me talk about the postoperative mortality of rectal cancer.

How much is the mortality rate after rectum cancer operation

First, it is generally believed that the prognosis of young patients with colorectal cancer is poor, especially the young patients under 30 years old. Specific analysis shows that the clinical symptoms of young people are not obvious, most of them are stage III and IV cases at the time of diagnosis, and the probability of radical operation is relatively low.

Second, it is generally believed that the prognosis of men and women is different due to the differences in anatomy and physiology, and the prognosis of men is worse than that of women. Multivariate analysis of 743 cases of colorectal cancer in Cancer Institute of Zhejiang University showed that the 5-year survival rate of women over 65 years old was significantly better than that of men. This phenomenon is more obvious in rectal cancer. In colon cancer cases, the 10-year survival rate of female patients was slightly higher than that of male patients.

Third, the location of colorectal cancer also affects the prognosis. It is generally believed that the farther away from the anus, the better the prognosis. The prognosis of rectal cancer is also closely related to the location of the tumor. The prognosis of patients with tumor located in the lower 1 / 3 of the rectum is poor. The prognosis of rectal cancer with more than peritoneal recurrences is better than that with less than peritoneal recurrences.

matters needing attention

In the selection of multiple targeted drugs for treatment, it should be noted that the target of the two targeted drugs is different, because the current clinical research data show that when the targeted drugs are added to the treatment, the efficacy does not increase, and the survival time of patients after drug treatment does not extend.